Why the study?
Catheter ablation for symptomatic non-paroxysmal atrial fibrillation remains challenging, with frequent clinical failure and need for continued therapy, prompting the need for guidance on patient selection and workflows for hybrid ablation.
This review provides clinical guidance on patient selection and workflow development for hybrid ablation in patients with advanced forms of atrial fibrillation.
Informs Hybrid Convergent workflows in non-paroxysmal AF; leaves open prospective validation before routine adoption.
Catheter ablation for treatment of symptomatic non-paroxysmal atrial fibrillation remains challenging. Clinical failure and need for continued medical therapy or repeat ablation is common, especially in more advanced forms of atrial fibrillation. Hybrid ablation has emerged as a more effective and safe therapy than endocardial-only ablation particularly for longstanding persistent atrial fibrillation as demonstrated by the randomized controlled CONVERGE trial. Hybrid ablation requires collaboration of electrophysiologists and cardiac surgeons to develop specific workflows. This review describes the Hybrid Convergent approach in the context of available ablation options and offers guidance for workflow development and patient selection.
No takes yet. Share an insight, caveat, or question.
David B. DeLurgio (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: